Rapid reversal of no-reflow using Abciximab after coronary device intervention

David Rawitscher, Thomas N. Levin, Ian Cohen, Ted Feldman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


The no-reflow phenomenon is a reduction in epicardial coronary artery blood flow without mechanical vessel obstruction. Early descriptions of this syndrome involved reperfusion after myocardial infarction. More recently, the no-reflow phenomenon has been recognized after brief ischemic times associated with coronary interventions. It is clearly a negative prognostic indicator. The proposed mechanism is multi-factorial and may involve small vessel vasospasm and potentially platelet-mediated loss of capillary autoregulation. Because of the potential role of platelets in the genesis of the no-reflow state, we administered Abciximab to two patients with no- reflow phenomenon following catheter interventions. In both of these settings, rapid distal runoff was reestablished within minutes after treatment with the platelet glycoprotein 2B/3A inhibitor.

Original languageEnglish (US)
Pages (from-to)187-190
Number of pages4
JournalCatheterization and cardiovascular diagnosis
Issue number2
StatePublished - Oct 1997


  • No-reflow
  • PTCA
  • Platelet inhibitor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Rapid reversal of no-reflow using Abciximab after coronary device intervention'. Together they form a unique fingerprint.

Cite this